Investors looking for consistency should turn to Alcon , JPMorgan said. The bank upgraded the eye care stock to overweight from neutral Thursday. It also raised its price target to $89.30 per share from $79.80. JPMorgan's forecast implies roughly 11% upside from Wednesday's $80.24 close. JPMorgan's call comes after Alcon, which makes Opti-Free contact lens solution, reported better-than-expected second-quarter results Wednesday. The company also raised its full-year earnings guidance. However, the stock only rose marginally on the back of that report. But analyst David Adlington says that even...